Cancer drug prices set to drop as Kenya seals deal with Pfizer
Cancer patients in Kenya are set to benefit from significantly lower medicine costs following an agreement between the Kenya Medical Supplies Authority (KEMSA) and US pharmaceutical company Pfizer...
✨ Key Highlights
Kenya has secured a significant deal with pharmaceutical giant Pfizer to dramatically reduce the cost of cancer medicines for patients. This agreement, signed under Pfizer’s Accord for a Healthier World programme, is expected to cut treatment expenses by over seven times for several types of cancer.
- Treatment costs for cancers like breast, stomach, and lung cancer could drop from as high as Ksh1 million to less than Ksh50,000 per cycle.
- The agreement was announced by President William Ruto following a meeting with Pfizer Chairman and CEO Albert Bourla.
- The deal will also grant Kenya earlier access to newer cancer drugs, potentially eliminating the current 10-year waiting period, and will support local pharmaceutical manufacturing in Africa.
Continue Reading
Read the complete article from KBC Top Stories
Part of the Day's Coverage
Kenya Seals Deal with Pfizer to Cut Cancer Drug Prices Sevenfold - September 2026
President William Ruto announced a landmark deal with pharmaceutical giant Pfizer that will drastically reduce the cost of cancer drugs in Kenya, cutting prices by more than sevenfold. Kenya secured the deal under Pfizer's Accord for a Healthier World programme, expected to cut treatment expenses by over seven times for several types of cancer. Separately, Kenya is intensifying efforts to implement universal infant screening for sickle cell disease, aiming to improve early diagnosis and treatment for the estimated 250,000 people living with the condition. The Africa Centres for Disease Control and Prevention was appointed to represent regional health organizations globally on the Joint Task Force on Global Health Architecture Reform.
